8 Results for "

proteolysis targeting molecule

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "proteolysis targeting molecule" in MCE Product Catalog:

Cat. No.: HY-145898
CAS No.: 2095780-08-6
Purity:  ≥95.0%
Synonyms: 14-D-Valine-TPL
Target:  

c-Myc Molecular Glues

Research Areas:  

Cancer

WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active c-Myc molecule glue degrader. WBC100 is a c-Myc degrader and targets ubiquitin E3 ligase CHIP mediated 26S proteasome pathway. WBC100 is used for c-Myc overexpressing tumors research .
loading...
    loading...
Cat. No.: HY-W453715
CAS No.: 2740657-28-5
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

Thalidomide-4-F,5-Br is a Thalidomide analogue. Thalidomide recruits E3 ligase for the ubiquitinylation and subsequent proteolysis of a target protein. This molecule may be derivatized through substitution at fluorine or bromine.
loading...
    loading...
Cat. No.: HY-L151
537 compounds

PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.

MCE supplies a unique collection of 537 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

Cat. No.: HY-130646
CAS No.: 2472645-27-3
Target:  

PROTACs PARP

Research Areas:  

Cancer

iVeliparib-AP6 is a proteolysis-targeting chimera (PROTAC) molecule designed based on Veliparib (HY-10129), which targets PARP1/2. The DC50s of iVeliparib-AP6 for inducing the degradation of PARP1 and PARP2 are 36 nM and 63 nM, respectively, and its IC50s are 69 nM and 21 nM, respectively. iVeliparib-AP6 contains a Veliparib-based PARP inhibitor warhead linked to a CRBN E3 ligase binder; it uses Thalidomide (HY-14658) as a ligand to recruit CRBN E3 ubiquitin ligase and exerts the PARP2 degradation mechanism .
loading...
    loading...
Cat. No.: HY-L128
188 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest(target binder). Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation.

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 188 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

Cat. No.: HY-L129
125 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest(target binder). Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 125 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Cat. No.: HY-183439
CAS No.: 2365116-48-7
Target:  

PROTACs FKBP

Research Areas:  

Cancer

dTAG-Fluorescein is a fluorescent acceptor probe and heterobifunctional proteolysis targeting chimeric molecule (PROTAC) .dTAG-Fluorescein functions in Homogeneous Time Resolved Fluorescence (HTRF) competitive displacement binding assays to measure binding affinity to His-FKBP12(F36V) .dTAG-Fluorescein recruits von Hippel-Lindau or CRBN E3 ligase complexes to drive selective degradation of FKBP12 F36V-tagged proteins, with limited activity towards FKBP12 WT and IKZF1 .
loading...
    loading...
Cat. No.: HY-L147
949 compounds

A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. Proteases play important roles in regulating multiple biological processes in all living organisms, such as regulating the fate, localization, and activity of many proteins, modulating protein-protein interactions, creating new bioactive molecules, contributing to the processing of cellular information, and generating, transducing, and amplifying molecular signals.

Proteases are important targets in drug discovery. Some protease inhibitors are often used as anti-virus drugs and anti-cancer drugs. MCE offers a unique collection of 949 protease inhibitors. MCE Protease Inhibitor Library is critical for drug discovery and development.